Vitamed, Rekah Group Overview
Vitamed is a generic pharmaceutical manufacturer and part of Rekah Pharmaceutical Industries. Vitamed is working to increase its international presence by focusing on out-licensing, in-licensing, establishing new partnerships, and executing mergers and acquisitions. Rekah Group is active at all levels of the value chain: production, R&D, marketing, sales, distribution, import, and export. The portfolio, which includes a wide range of 280 generic prescription and over-the-counter drugs, dermo-cosmetics, vitamins, and nutritional supplements, focuses on four core fields: steroids, antibiotics, ophthalmic medications, and over-the-counter drugs. The group operates research and development laboratories at its production sites in Holon and Binyamina.
Latest News
growth-positive
Nifty clocks fifth session of gains led by IT on Infosys buyback, US rate cut hopes
Infosys led gains in Indias Nifty 50 index, which closed higher for the fifth consecutive session, driven by a 5% surge in Infosys shares following the announcement of a share buyback plan. The IT sector, which accounted for a significant portion of the days gains, benefited from expectations of a U.S. interest rate cut, which could boost technology spending in the U.S., a key market for Indian IT firms. The broader market also saw gains, with the Nifty 50 and BSE Sensex both rising by 0.39%. The anticipation of a Federal Reserve rate cut was fueled by weaker-than-expected U.S. job data.
growth-positive
Nikkiso Addresses Growing Ammonia-Handling Demand and Launches Next-Generation Pump at Gastech 2025
Nikkiso Clean Energy & Industrial Gases Group (Nikkiso CE&IG) announced the launch of a next-generation submerged ammonia pump at the Gastech Conference. This pump is designed to be the safest and most reliable in the industry, addressing common maintenance issues with its seal-less, maintenance-friendly, copper-free construction. The pump can deliver over 2,500m3 per hour and has a mean time between outages of over 16,000 hours. This launch is part of Nikkiso CE&IGs ongoing innovation in ammonia handling, with the company having decades of experience in this field. The pump is expected to meet growing demand for ammonia in various sectors, including power generation and shipping.
Product Stage
growth-positive
Westin Desaru Coast Resort partners with CAYIN Technology for digital signage
CAYIN Technology has partnered with Westin Desaru Coast Resort in Johor, Malaysia, to enhance guest communication and operational efficiency through the implementation of its CMS-WS server and CAYIN Signage Player. This collaboration involves the use of digital signage to provide real-time updates across 14 Samsung displays in various areas of the resort. The project was executed in partnership with Hola Media, which provided integration services, including installation, design, staff training, and support. The system has improved communication, reduced staff workload, and enhanced the guest experience, preparing the resort for future digital expansion.
Partners
growth-positive
BHP Xplor Opens Applications for 2026 Cohort, Offering Equity-Free Funding and Global Support
BHP Group Limited has announced the opening of applications for the 2026 cohort of its BHP Xplor accelerator program, which aims to transform the discovery of critical minerals. The program offers early-stage explorers up to USD $500,000 in equity-free funding, mentorship, and access to BHP’s global network. BHP Xplor has been successful in previous years, fostering partnerships and accelerating exploration projects. The program supports BHPs long-term growth by engaging with diverse exploration projects. Applications are open from September 8 to October 15, 2025.
Partners
growth-positive
Assessing the Valuation of Yue Yuen Industrial (SEHK:551) After Recent Volatility
Yue Yuen Industrial (Holdings) has experienced notable stock price fluctuations, drawing attention from investors. Despite a year-to-date decline of 21%, the company has shown resilience with an 11% gain over the past year and a 13% increase in the past three months. Over a longer period, the stock is up 53% over three years and 44% over five years. The companys P/E ratio of 7.2x suggests it is undervalued compared to industry peers, indicating potential for growth if profit levels are sustained or improved. While the company shows steady revenue and net income growth, risks remain due to inconsistent short-term returns and potential shifts in market sentiment.
| Sector | Health Tech & Life Sciences |
Funding
| Total funding | Undisclosed |
| Last funding | Undisclosed |
| Stage | Public |
| Rounds | 1 |
| Investors | 0 |
Team Members
3
Employees: 11-50
Web & Social Links
| Website | rekah.co.il |
Locations
HaMelacha Street 30, Holon, Israel
Photos & Videos
4 item(s)
